Tracy Robson

Publisher：朱苏静Release time：2024-02-11Views：372

Email:tracyrobson@rcsi.com

Tel:01-4022582

Add:1st Floor Ardilaun House, Block B, 111 St. Stephen's Green, Dublin 2., Ireland





Biography

Professor Tracy Robson obtained her PhD in Molecular Radiation Science from Imperial College, London (1996). Her first academic post was as Lecturer in Radiation Science at Ulster University in 1997; she was promoted to Reader in 2001. She then moved to the School of Pharmacy, Queen’s University of Belfast in 2004 to take up the post of Reader in Molecular Pharmacology; she was promoted to Professor of Experimental Therapeutics in 2010. She joined RCSI as Professor and Head of Molecular & Cellular Therapeutics (MCT) in August 2016. Her research has led to the development of a first-in-class drug, five patents, more than >80 original research publications and funding in excess of 7.5 M Euros mostly from Industry, UK research councils, MRC & BBSRC, and national charities, Cancer Research UK, Breast Cancer Now, Prostate Cancer Charity, HPSS R&D Office, and more recently the National Children's Research Centre, Dublin. She assumed the position of Head of School of Pharmacy, RCSI, merging the School of Pharmacy with the Department of Molecular and Cellular Therapeutics to form a new School, July 2019. This new School is renamed School of Pharmacy and Biomolecular Sciences (PBS).


Research Interests

Her major research focus has been the development of novel approaches for sensitizing tumours to therapy using personalised medicine approaches. She led a major programme of research aimed at the identification and functional characterisation of genes that alter tumour response to anti-cancer agents. In particular, she cloned and characterized a novel human gene, FKBPL. Her group has demonstrated an extracellular role for FKBPL as a naturally secreted, anti-angiogenic protein. Together with Almac, she led the development of therapeutic peptide derivatives (AD-01 and ALM201) based on FKBPL’s active anti-angiogenic domain. Based on the robust efficacy and excellent safety profile, ALM201, a ‘first-in-class’ FKBPL-based anti-angiogenic therapeutic peptide has completed formulation and toxicology testing and has entered phase I/II cancer clinical trials (EudraCT number: 2014-001175-31). More recently, ALM201 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) in the treatment of ovarian cancer. More recently, through the development of genetically modified mouse models, she has also demonstrated a role for FKBPL in protection against a range of other diseases associated with vascular regulation and inflammation. She is actively researching in these areas, so that the clear translational potential of FKBPL-based therapeutics can be fully harnessed and FKBPL’s diagnostic potential in these disease settings can be scrutinized. Check out more about the Robson research group on: https://robsonlab.com/our-lab/


Recent Publications


All rights reserved © INTERNATIONAL COLLEGE OF PHARMACEUTICAL INNOVATION